Side Effect Prevention Training (SEPT) for Nocebo Effects in Breast Cancer Patients
Female Breast Cancer
About this trial
This is an interventional prevention trial for Female Breast Cancer focused on measuring Randomized Controlled Trial, Patients´ Expectations, Breast Cancer, Adjuvant Endocrine Treatment, Nocebo
Eligibility Criteria
Inclusion Criteria:
- Women with estrogen receptor positive breast cancer scheduled to start first-line adjuvant endocrine therapy with Tamoxifen (+/- GnRH) or a third generation Aromatase inhibitor at the Breast Cancer Centre
- Sufficient knowledge of German language and ability to give informed consent
- Age of 18 and more
Exclusion Criteria:
- Presence of a serious comorbid psychiatric condition (schizophrenia or addiction, severe depression or anxiety)
- Presence of a life threatening comorbid medical condition
Sites / Locations
- University Medical Center Hamburg-Eppendorf
Arms of the Study
Arm 1
Arm 2
Arm 3
No Intervention
Experimental
Active Comparator
Standard Medical Care and Information
Side effect prevention training (SEPT)
Attention Control group (ACG)
Patients receive standard treatment protocol for breast cancer patients and additional oral and written information about adjuvant endocrine treatment.
Patients receive standard medical care and a brief behavioral intervention that targets patients' response and coping expectations while starting with adjuvant endocrine treatment.
Patients receive standard medical care and a comparable amount of therapist´s attention (common and unspecific factors) to the intervention group without targeting patients´ expectations.